NCT07060807 2026-04-16A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Merck Sharp & Dohme LLCPhase 3 Recruiting1,000 enrolled
NCT06324357 2026-04-15Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadBoehringer IngelheimPhase 1/2 Recruiting768 enrolled
NCT06764875 2026-04-09A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerAstraZenecaPhase 3 Recruiting840 enrolled
NCT05950945 2026-04-08Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerDaiichi SankyoPhase 3 Recruiting250 enrolled
NCT05048797 2026-04-03A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsAstraZenecaPhase 3 Active not recruiting454 enrolled
NCT07497386 2026-03-27A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast CancerJiangsu HengRui Medicine Co., Ltd.Phase 2 Not yet recruiting150 enrolled